Organ transplant immunosuppressant market analysis
According to Technavio’s market research report, the global organ transplant immunosuppressant market will grow at a CAGR of close to 4% during the forecast period. One of the key drivers that will propel the growth prospects for the market during the estimated period is the complications associated with organ transplantation. The recipient body recognizes the transplanted organ or tissue as a foreign body and triggers a blood transfusion reaction. This leads to transplant rejection as a response to the recipient's immune system.
Transplant rejections can be of three types, which includes hyperacute rejection, acute rejection, or chronic rejection. This results in the emergence of immunosuppressive therapy, which is used to achieve a successful organ transplant. Cyclosporine is one of the best immunosuppressants and has established a benchmark of successful immunosuppression.
Get A Free Sample
Organ transplant immunosuppressant market size based on geography
Countries such as the US, Mexico, Canada, Brazil, Argentina, and Colombia are contributing to the growth of the global organ transplant immunosuppressant market. The availability of developed infrastructure and the rising number of transplantation procedures will boost the application of organ transplant immunosuppressants in the Americas from 2017 to 2021.
Organ transplant immunosuppressant market worth: Competitive landscape and key vendors
The global organ transplant immunosuppressant market is highly concentrated due to the presence of many small and large vendors. These vendors highly focus on offering branded and generic immunosuppressive therapies to expand their customer base. To retain their market shares, vendors are trying to develop enhanced immunosuppressants.
Key vendors in the organ transplant immunosuppressant market
- Astellas Pharma
- Novartis
- Pfizer
- Sanofi
Organ transplant immunosuppressant market by drug class
- Selective inhibitor of cytokine production and function
- Immunosuppressive antimetabolites
- Immunosuppressive antibodies
- Immunosuppressive adrenocorticosteroids
The selective inhibitor of cytokine production and function drug class accounted for the majority market share during 2016. The conventional immunosuppressive therapy involves the application of selective inhibitors of cytokine production and function and antimetabolites such as MMF. However, this may result in late acute rejection episodes and graft losses. Consequently, the application of tacrolimus formulation along with a selective inhibitor of cytokine helps to overcome this problem. The continual dependence of surgeons on the selective inhibitor of cytokine drug class will drive the segment’s growth for the next four years.
Organ transplant immunosuppressant market by therapeutic application
- Kidney transplantation
- Liver transplantation
- Heart transplantation
- Lung transplantation
- Pancreas transplantation
The kidney transplant immunosuppressant accounted for the maximum market shares during 2016. The sales volume of kidney transplant immunosuppressants will continue to increase in the forthcoming years due to the rising private-public funding for the development of human leukocyte antigen (HLA) typing technology and solid organ-based transplantation.
Want a bigger picture? Try a FREE sample of this report now!
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Key questions answered in the report include
- What will the market size and the growth rate be in 2021?
- What are the key factors driving the global organ transplant immunosuppressant market?
- What are the key market trends impacting the growth of the global organ transplant immunosuppressant market?
- What are the challenges to market growth?
- Who are the key vendors in the global organ transplant immunosuppressant market?
- What are the market opportunities and threats faced by the vendors in the global organ transplant immunosuppressant market?
- What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
- What are the key outcomes of the five forces analysis of the global organ transplant immunosuppressant market?
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Introduction to organ transplantation
- What is an organ transplantation?
- How common is organ transplantation?
- Increasing trend of organ transplantation
- Need for immunosuppression during organ transplant
- What is an immunosuppressant?
- Role of an immunosuppressant during organ transplant
PART 06: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 07: Key clinical trials
PART 08: Market segmentation by drug class
- Selective inhibitor of cytokine production and function
- Immunosuppressive antimetabolites
- Immunosuppressive antibodies
- Immunosuppressive adrenocorticosteroids
PART 09: Market segmentation by therapeutic application
- Kidney transplantation
- Liver transplantation
- Heart transplantation
- Lung transplantation
- Pancreas transplantation
- Other transplantation
PART 10: Geographical segmentation
- Organ transplant immunosuppressant market in Americas
- Organ transplant immunosuppressant market in EMEA
- Organ transplant immunosuppressant market in APAC
PART 11: Decision framework
PART 12: Drivers and challenges
- Market drivers
- Market challenges
PART 13: Market trends
- Growing trend of medical tourism
- New government initiatives on transplant research programs
- Growing focus toward the use of biologics
PART 14: Vendor landscape
PART 15: Key vendor analysis
- Astellas Pharma
- Novartis
- Pfizer
- Sanofi
- Other prominent vendors
PART 16: Appendix